Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.71 USD | +2.45% | -0.65% | -46.63% |
04-23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
04-22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
Business Summary
Number of employees: 598
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 517 | 100.0 % | 726 | 100.0 % | +40.45% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 517 | 100.0 % | 726 | 100.0 % | +40.45% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14/07/14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 27/05/20 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 31/10/22 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/21 |
Brendan Teehan
COO | Chief Operating Officer | 56 | 30/06/18 |
Ponni Subbiah
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/19 |
- | - | ||
Kimberly Manhard
PRN | Corporate Officer/Principal | 64 | 01-29 |
Kevin Oliver
PRN | Corporate Officer/Principal | - | 09/07/23 |
Holly Valdiviez
SAM | Sales & Marketing | - | 31/03/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 10/12/15 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 24/11/15 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14/07/14 |
Don Soland
BRD | Director/Board Member | 65 | 19/03/15 |
Laura Brege
BRD | Director/Board Member | 66 | 30/04/08 |
Stephen Biggar
CHM | Chairman | 53 | 21/01/13 |
James Daly
BRD | Director/Board Member | 63 | 10/01/16 |
Director/Board Member | 66 | 28/09/20 | |
Adora Ndu
BRD | Director/Board Member | 43 | 09/10/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 164,771,521 | 163,859,371 ( 99.45 %) | 0 | 99.45 % |
Company contact information
ACADIA Pharmaceuticals, Inc.
12830 El Camino Real Suite 400
92130-3331, San Diego
+858 558 2871
http://www.acadia.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.63% | 2.75B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ACAD Stock
- Company ACADIA Pharmaceuticals Inc.